Abstract:Background: Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by a multi-factorial etiology that is not completely understood. Donepezil is a first-line acetylcholinesterase inhibitor used for the treatment of AD that has been found, in addition to its potent acetylcholinesterase inhibitory effect, to act through other non-cholinergic mechanisms such as affecting mitochondrial biogenesis through peroxisome proliferator-activated receptor gamma coactivator (PGC1α). Mitochondrial biogenesis and PGC-1α, at least in part, are associated with hepatic fatty acid oxidation and ketogenesis. Whether donepezil regulates ketogenesis in AD treatment remains unclear. Ketogenesis is important in the progression of AD and is a critical consideration during the therapeutic strategy selection for AD. Thus, our goals were to determine the differences in ketone bodies in patients with AD who were taking donepezil treatment and those who were not, to elucidate the potential effect of AD and donepezil therapy on ketone body metabolic parameters, and to discover the effect of donepezil therapy on ketogenesis in patients with AD. Methods: Cross-sectional analysis was performed on plasma collected from 145 individuals, namely, elderly adults as healthy controls (n=30), newly diagnosed patients with AD (n=30), patients with AD who responded to donepezil therapy (n=48) and patients with AD who did not respond to donepezil therapy (n=37). Gas chromatography-mass spectrometry was performed to quantify the lipids in the plasma. The level of β-hydroxybutyrate, a metabolite, was determined by liquid chromatographytandem mass spectrometry, and to gain further insight into the effect of donepezil on ketogenesis, the effects of donepezil were investigated in a mouse model. Results: The level of β-hydroxybutyrate decreased in AD patients, and donepezil elevated the plasma level of β-hydroxybutyrate. Donepezil increased the plasma and liver levels of β-hydroxybutyrate in mice as well as the hepatic expression of PGC-1α and the mitochondrial expression of HMG-CoA synthetase 2 (HMGCS2) in response to fasting, causing a subsequent increase in ketogenesis. Conclusions: Our study revealed that impaired ketogenesis is a metabolic feature of AD. Donepezil had effects on ketogenesis in mice and reversed the decrease in the level of β-hydroxybutyrate found in patients with AD.

Effects of Donepezil Treatment on Plasma and Urine Metabolites in Amyloid Beta-Induced Alzheimer's Disease Rats

Effect of intraperitoneal pentobarbital injection or isoflurane inhalation anesthesia on the rat acute stress response

Effects of Donepezil Treatment on Brain Metabolites, Gut Microbiota, and Gut Metabolites in an Amyloid Beta-Induced Cognitive Impairment Mouse Pilot Model

Acetylcholinesterase Inhibitor Donepezil Effects on Plasma Β-Hydroxybutyrate Levels in the Treatment of Alzheimer’s Disease

Effects of donepezil on cognitive functions and the expression level of β-amyloid in peripheral blood of patients with Alzheimer's disease

Therapeutic effect of Donepezil hydrochloride on Alzheimer's disease rats

Investigation of Plasma Metabolomics and Neurotransmitter Dysfunction in the Process of Alzheimer's Disease Rat Induced by Amyloid Beta 25-35

Study On Urine Metabolic Profile Of A Beta 25-35-Induced Alzheimer'S Disease Using Uhplc-Q-Tof-Ms

Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice

Hippocampal Proteomic Alteration in Triple Transgenic Mouse Model of Alzheimer's Disease and Implication of PINK 1 Regulation in Donepezil Treatment

ChemInform Abstract: Donepezil‐Induced Neuroprotection of Acetylcholinergic Neurons in Olfactory Bulbectomized Mice

Effects of BIS-MEP on Reversing Amyloid Plaque Deposition and Spatial Learning and Memory Impairments in a Mouse Model of Β-Amyloid Peptide- and Ibotenic Acid-Induced Alzheimer’s Disease

Studies on Diagnostic Biomarkers and Therapeutic Mechanism of Alzheimer's Disease Through Metabolomics and Hippocampal Proteomics.

P2-105: the Effects of Donepezil on Alzheimer's Disease: A Diffusion Tensor Imaging Study at 3T

[Different processed products of Polygonati Rhizoma treat Alzheimer's disease in rats: urine metabolomics based on UPLC-Q/TOF-MS]

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease

Clinical study for the treatment of donepezil on patients with Alzheimer disease

In Vitro Metabolism of Donepezil in Liver Microsomes Using Non-Targeted Metabolomics

Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping

Association between long‐term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using 18 F‐AV‐45 and 18 F‐AV‐1451 PET

The Effects of Donepezil on Phencyclidine-Induced Cognitive Deficits in a Mouse Model of Schizophrenia